IMI 2 DO IT Big Data for Better Outcomes Coordination and Support Action


01/02/2017 – 31/01/2019

About the project

Big Data for Better Outcomes (BD4BO) programme was launched in 2015 within the framework of the IMI2 programme. BD4BO programme aims to maximise the potential of large datasets (big data) in order to support and promote patient and outcome focused healthcare in Europe as well as developing innovative methods for using big data. BD4BO willl ensure a platform for bringing together the disease specific projects of IMI2. The Coordination and Support Action (CSA) will support all of the projects of BD4BO programme in the following Work Packages:

  • WP1 Strategy Development
  • WP2 Knowledge Repository
  • WP3 Dissemination
  • WP4 Data Privacy

HSMTC is the WP leader in WP3 and active member of the other WPs too.


Consortium leader: London School of Economics and Political Science (LSE)

Role of HSMTC: Consortium member

Consortium members:

  • Novartis (NVS)
  • National Institute for Health and Care Excellence (NICE)
  • Dental and Pharmaceutical Benefits Agency (TLV)
  • European Cancer Patient Coalition (ECPC)
  • European Multiple Sclerosis Platform (EMSP)
  • Imperial College London (ICL)
  • Swedish Institute for Health Economics (IHE)
  • Centre for Research in Healthcare Management (CERGAS), Università Bocconi
  • Norwegian Institute of Public Health (NIPH)
  • National Quality Registries at the Swedish Association of Local Authorities and Regions (SKL)
  • The Association of the British Pharmaceutical Industry (ABPI)
  • Amgen (AMGEN)
  • Bayer (BAY)
  • Boehringer Ingelheim (BI)
  • Celgene (CELGENE)
  • European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • Farmaindustria (FI)
  • GlaxoSmithKline (GSK)
  • Health iQ (HIQ)
  • Intersystems (INTSYS)
  • Janssen Pharmaceutica NV (JANSSEN)
  • Eli Lilly and Company (LILLY)
  • Merck Group (MERCK)
  • MSD Sharp & Dohme (MSD)
  • Novo Nordisk (NOVO)
  • Pfizer (PFIZER)
  • Roche (ROCHE)
  • Sanofi (SARD)
  • Servier (IRIS)
  • UCB (UCB)
  • Association of Research-Based Pharmaceutical Companies (VFA)
  • Norwegian Medicines Agency (NOMA)
  • Technology, Methods and Infrastructure for Networked Medical Research (TMF)
  • Inserm Toulouse (INSERM)

HSMTC contact

Name: László Bencze
Phone: +36 1 488 7635